Korro Bio, Inc. (KRRO)

Korro Bio's stock has been significantly impacted by several events in the past six months. The company announced that KRRO-110 produced functional protein in AATD patients but did not achieve projected protein levels, leading to a strategic pivot, workforce reduction, and paused collaboration with Novo Nordisk. This resulted in a stock decline. H.C. Wainwright flagged KRRO-121 as an independent value driver, and Piper Sandler upgraded Korro Bio. The 52-week trading range for KRRO has been between $5.20 and $55.89.

Information regarding demand seasonality for Korro Bio, Inc.'s products and services is not available. Demand is typically driven by disease prevalence, unmet medical needs, and the success of clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Korro Bio operates in the Biotechnology & Medical Research sector, specifically in Drug Discovery. The company's pipeline includes RNA editing therapies, with its lead candidate, KRRO-110, in Phase 1/2a clinical trial for Alpha-1 Antitrypsin Deficiency (AATD). Other programs target Urea Cycle Disorders/Hepatic Encephalopathy, AATD using a GalNAc-conjugated program, AMPKγ1/Longevity (Liver), and Amyotrophic Lateral Sclerosis (ALS).

Korro Bio, Inc. is headquartered in Cambridge, Massachusetts, United States. Its operations, including the discovery, development, and commercialization of its genetic medicines, are primarily conducted in the United States.

Korro Bio's brand reputation has been negatively affected by disappointing clinical trial results for KRRO-110, subsequent workforce reduction, and the pausing of the collaboration with Novo Nordisk. Analyst ratings currently show a consensus of "Hold" for Korro Bio, with an average rating score of 2.10. MarketBeat's evaluation placed Korro Bio higher than 41% of companies in its assessment.

Korro Bio, Inc. has a significant institutional ownership presence, with major holders including Atlas Venture Life Science Advisors, LLC, NEA Management Company, LLC, and Vanguard Group Inc. Individual ownership includes Dr. Nessan Bermingham and Ali Behbahani, M.D. The company's executive officers, directors, and principal stockholders collectively have the ability to control or significantly influence matters submitted to stockholders for approval.